60 patients from primary care that fulfil selection criteria. Signing of informed consent

Randomisation

Memantine Group (n=30)  Placebo Group (n=30)

1st visit (baseline assessment). Evaluation of study variables (neuroimaging tests and administration of questionnaires)
Administration of memantine/placebo

Progressive increase of the dose to a daily intake of 20 mg of memantine/placebo.
2nd visit (1 month assessment): administration of questionnaires.

Dose of 20mg of memantine/placebo
3rd visit (3 month assessment). Evaluation of study variables (administration of questionnaires)

Dose of 20mg of memantine/placebo.
4th visit (6 month assessment). Evaluation of variables (neuroimaging tests and questionnaires)